Skip to content
Article Rich – Lifestyle
Author:
Ipsen Pharma
Ipsen appoints Michelle C. Werner as EVP, President of North America
March 12, 2026
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
March 9, 2026
Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma
March 5, 2026
←
Previous Page
1
2